| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
At a lower dose than Celecoxib, Polmacoxib (CG100649) (0-1 μg/ml; 24 hours; HCA-7 and HT-29 cells) can reduce PGE2 synthesis and COX-2 activity in human colon cancer cells[2].
|
|---|---|
| ln Vivo |
In ApcMin/+ mice, polmacoxib (7 mg/kg; oral; once daily for 8 weeks) prevents the formation of intestinal polyps [2]. Tumor weight and volume were reduced by 58% and 48%, respectively, with polmacoxib (7–15 mg/kg); oral; once daily on days 27 to 111 postinjection; athymic nude mice; subcutaneous xenograft mouse model). % and 36%, respectively, following celecoxib therapy [2]. Orthotopic xenograft mouse models treated with polmacoxib (7–15 mg/kg; oral; starting on day 14 and continuing for 8 weeks; athymic nu/nu mice); this inhibits the growth of colorectal cancer (CRC) in these models. Tumor weight was reduced by 70% with 7 mg/kg or 83% with 15 mg/kg, in contrast to a 70% reduction following treatment with 500 mg/kg celecoxib [2].
|
| References |
|
| Additional Infomation |
Polmacoxib has been used in trials studying the treatment of Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Localized Primary Osteoarthritis of Hip, and Localized Primary Osteoarthritis of Knee.
|
| Molecular Formula |
C18H16FNO4S
|
|---|---|
| Molecular Weight |
361.38734
|
| Exact Mass |
361.078
|
| CAS # |
301692-76-2
|
| PubChem CID |
9841854
|
| Appearance |
Light yellow to green yellow solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
672
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IJWPAFMIFNSIGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
|
| Chemical Name |
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide
|
| Synonyms |
CG 100649; CG-100649; CG100649
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~691.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7671 mL | 13.8355 mL | 27.6709 mL | |
| 5 mM | 0.5534 mL | 2.7671 mL | 5.5342 mL | |
| 10 mM | 0.2767 mL | 1.3835 mL | 2.7671 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
